Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 26 studies | 34% ± 18% | |
| epithelial cell | 10 studies | 37% ± 19% | |
| myofibroblast cell | 10 studies | 35% ± 15% | |
| mesothelial cell | 9 studies | 59% ± 22% | |
| secretory cell | 8 studies | 45% ± 18% | |
| respiratory goblet cell | 7 studies | 45% ± 15% | |
| connective tissue cell | 7 studies | 32% ± 12% | |
| club cell | 6 studies | 38% ± 8% | |
| basal cell | 6 studies | 28% ± 15% | |
| ciliated cell | 5 studies | 39% ± 10% | |
| adventitial cell | 5 studies | 59% ± 13% | |
| goblet cell | 5 studies | 31% ± 18% | |
| duct epithelial cell | 4 studies | 89% ± 5% | |
| adipocyte | 4 studies | 17% ± 1% | |
| glutamatergic neuron | 4 studies | 27% ± 11% | |
| enterocyte | 3 studies | 21% ± 4% | |
| transit amplifying cell | 3 studies | 19% ± 1% | |
| serous secreting cell | 3 studies | 26% ± 2% | |
| GABAergic neuron | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 95% | 4343.22 | 548 / 578 | 87% | 63.74 | 1002 / 1155 |
| bladder | 95% | 5768.81 | 20 / 21 | 78% | 233.84 | 391 / 504 |
| prostate | 94% | 6851.92 | 231 / 245 | 75% | 44.76 | 378 / 502 |
| ovary | 91% | 4349.47 | 163 / 180 | 77% | 93.44 | 333 / 430 |
| intestine | 82% | 2038.27 | 792 / 966 | 76% | 49.15 | 398 / 527 |
| breast | 80% | 3845.01 | 367 / 459 | 75% | 99.46 | 841 / 1118 |
| uterus | 69% | 3013.76 | 118 / 170 | 65% | 156.79 | 299 / 459 |
| esophagus | 60% | 1740.29 | 873 / 1445 | 63% | 48.31 | 115 / 183 |
| pancreas | 27% | 368.37 | 88 / 328 | 92% | 124.44 | 163 / 178 |
| stomach | 41% | 1704.27 | 146 / 359 | 68% | 33.71 | 195 / 286 |
| kidney | 65% | 1824.57 | 58 / 89 | 43% | 29.76 | 391 / 901 |
| ureter | 0% | 0 | 0 / 0 | 100% | 55.34 | 1 / 1 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 47.11 | 27 / 29 |
| adrenal gland | 72% | 1567.29 | 186 / 258 | 8% | 2.41 | 19 / 230 |
| thymus | 66% | 1638.81 | 431 / 653 | 14% | 2.71 | 85 / 605 |
| blood vessel | 70% | 2115.72 | 930 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 64% | 8542.51 | 776 / 1204 | 0% | 0 | 0 / 0 |
| heart | 62% | 2790.15 | 538 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 60% | 26.65 | 27 / 45 |
| skin | 10% | 103.00 | 179 / 1809 | 46% | 17.13 | 218 / 472 |
| liver | 8% | 81.47 | 18 / 226 | 26% | 13.16 | 105 / 406 |
| muscle | 12% | 156.60 | 99 / 803 | 0% | 0 | 0 / 0 |
| brain | 0% | 1.82 | 3 / 2642 | 10% | 6.02 | 68 / 705 |
| spleen | 8% | 70.12 | 19 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.29 | 2 / 80 |
| peripheral blood | 1% | 21.79 | 10 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0005615 | Cellular component | extracellular space |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0016020 | Cellular component | membrane |
| GO_0005515 | Molecular function | protein binding |
| GO_0008191 | Molecular function | metalloendopeptidase inhibitor activity |
| Gene name | RARRES1 |
| Protein name | Retinoic acid receptor responder protein 1 (Phorbol ester-induced gene 1 protein) (PERG-1) (RAR-responsive protein TIG1) (Tazarotene-induced gene 1 protein) |
| Synonyms | TIG1 PEIG1 |
| Description | FUNCTION: Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle. . |
| Accessions | P49788 ENST00000237696.10 [P49788-1] ENST00000479756.1 [P49788-2] |